Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics news coverage focuses on clinical trial data releases, regulatory milestones, and business development activities related to its cancer immunotherapy pipeline. Investors and analysts closely monitor announcements regarding the company's Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform and clinical candidates including BDC-3042 and BDC-4182.
Clinical data presentations at major oncology conferences such as the American Association for Cancer Research (AACR) Annual Meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, and the Society for Immunotherapy of Cancer (SITC) Annual Meeting generate significant news coverage. These presentations provide insights into the safety, tolerability, and preliminary efficacy of the company's drug candidates across multiple solid tumor types.
Strategic partnership announcements represent another major category of news coverage for Bolt Biotherapeutics. Collaborations with pharmaceutical companies and biotechnology firms to develop new Boltbody ISAC candidates or advance existing programs often impact investor sentiment and stock performance. These partnerships validate the platform technology and provide additional resources for clinical development.
Regulatory developments including Investigational New Drug (IND) applications, clinical trial initiations, and interactions with health authorities drive news coverage. Updates on patient enrollment milestones, dose escalation progress, and expansion cohorts in ongoing clinical trials provide visibility into development timelines and program advancement.
Financial news coverage includes quarterly earnings reports, cash runway updates, and capital raising activities. As a clinical-stage company, Bolt Biotherapeutics requires ongoing funding to support research and development activities, making financing announcements particularly relevant to investors. The company's pipeline prioritization decisions and resource allocation strategies also generate investor interest and news coverage.
Scientific publications and preclinical data releases contribute to the news landscape, particularly when they validate the mechanism of action of the Boltbody ISAC platform or demonstrate activity in new tumor types or combination therapy settings. Patent grants and intellectual property developments also receive coverage as they strengthen the company's competitive position in the immuno-oncology space.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) has appointed Laura Berner to its Board of Directors as of December 14, 2022. Laura brings extensive experience in biopharmaceuticals, having executed over 50 transactions in her career. Her strategic insights are expected to support Bolt's ongoing development of its immunotherapy pipeline, particularly BDC-1001, which is advancing into Phase 2 clinical trials, and BDC-3042, slated for clinical evaluation. CEO Randall Schatzman expressed enthusiasm for her contributions, highlighting her potential to enhance Bolt's commitment to cancer treatment.
Bolt Biotherapeutics (BOLT) reported third-quarter 2022 results, highlighting the dose-escalation trials for BDC-1001 targeting HER2-expressing tumors, with recruitment on track for completion by year-end 2022. Collaboration revenue rose to $2.1 million, a 50% increase from the previous quarter. R&D expenses remained stable at $19.0 million, while G&A expenses increased to $5.5 million. The company’s cash balance stands at $209.6 million, expected to fund operations through 2025. Upcoming milestones include topline data from BDC-1001 and the initiation of BDC-3042 clinical studies in 2023.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) presented new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 SITC Annual Meeting in Boston. The innovative therapy aims to convert immunosuppressive tumor-associated macrophages into immunostimulatory cells, potentially enhancing anti-tumor immunity. Key findings include BDC-3042's ability to selectively activate these macrophages, thereby facilitating anti-tumor activity in preclinical models. Bolt is advancing BDC-3042 through IND-enabling studies as part of its commitment to developing novel cancer immunotherapies.
Bolt Biotherapeutics (Nasdaq: BOLT) will participate in the Stifel 2022 Healthcare Conference on Nov. 16, 2022, at 1:15 p.m. EST in New York. The event will feature a fireside chat with management, and a live webcast can be accessed on Bolt's website. The company is known for developing innovative immuno-oncology therapeutics, including BDC-1001 and BDC-3042, which target HER2 and modulate myeloid biology, respectively. Archived replays will be available for 30 days post-event.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focusing on immuno-oncology, announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.
The event will take place on September 13, 2022, at 12:20 p.m. ET in New York City. A live webcast will be accessible on Bolt's website, with archived replays available for 30 days post-event.
Bolt's pipeline includes innovative therapies targeting cancer, highlighting their commitment to advancing treatment options.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2022 financial results, highlighting $223.6 million in cash to fund operations through 2025. Clinical progress includes the ongoing BDC-1001 dosage studies, with anticipated data readouts later this year. The company has prioritized its pipeline, ceasing BDC-2034 due to off-target toxicity, while focusing on BDC-1001 and BDC-3042. Collaboration revenue rose to $1.4 million, a 75% increase from Q1 2022. R&D expenses fell slightly to $18.9 million, while G&A expenses rose to $5.5 million.
Bolt Biotherapeutics announces a presentation at the 2022 ASCO Annual Meeting in Chicago, showcasing data on myeloid cell presence in solid tumors, even with low T cell infiltration. The poster, titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)," highlights myeloid cells' potential as therapeutic targets. The insights could enhance the efficacy of myeloid-targeted therapies, benefiting patients resistant to T cell approaches. The abstract number is 2557, and the poster session is scheduled for June 5.
Bolt Biotherapeutics reported Q1 2022 financial results, showing collaboration revenue of $0.8 million, driven by R&D partnerships. R&D expenses rose to $18.4 million, reflecting progress in clinical trials and IND-enabling activities. General and administrative expenses increased to $6.3 million. The company holds a robust cash balance of $246.8 million, expected to fund operations and key milestones into 2024. The lead program, BDC-1001, is on track for data readouts in H2 2022, with promising early signs of clinical disease control.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotech firm, will present an overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 12:45 p.m. PT. The presentation will highlight Bolt's innovative immuno-oncology therapeutics that utilize Boltbody™ to target tumors. Key products include BDC-1001, a HER2-targeting agent in a Phase 1/2 trial, and others targeting CEA and Dectin-2. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event.
Bolt Biotherapeutics (BOLT) reported its financial results for Q4 and the full year 2021, showcasing a cash balance of $271.6 million to fund operations through 2024. The company is progressing with BDC-1001, a treatment for HER2-expressing solid tumors, expected to reach Phase 2 dose identification later in 2022. The ongoing combination study with OPDIVO® is advancing well, showing promising stability and partial responses. R&D expenses rose to $75.7 million, reflecting increased clinical trial costs. Total revenue for 2021 was $1.3 million, marking growth from $0.2 million in 2020.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
